Literature DB >> 10954754

Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas.

I S Lossos1, A A Alizadeh, M B Eisen, W C Chan, P O Brown, D Botstein, L M Staudt, R Levy.   

Abstract

B cell diffuse large cell lymphoma (B-DLCL) is a heterogeneous group of tumors, based on significant variations in morphology, clinical presentation, and response to treatment. Gene expression profiling has revealed two distinct tumor subtypes of B-DLCL: germinal center B cell-like DLCL and activated B cell-like DLCL. In a separate study, we determined that B-DLCL can also be subdivided into two groups based on the presence or absence of ongoing Ig gene hypermutation. Here, we evaluated the correlation between these B-DLCL subtypes established by the two different methods. Fourteen primary B-DLCL cases were studied by gene expression profiling using DNA microarrays and for the presence of ongoing mutations in their Ig heavy chain gene. All seven cases classified as germinal center B cell-like DLCL by gene expression showed the presence of ongoing mutations in the Ig genes. Five of the seven cases classified by gene expression as activated B cell-like DLCL had no ongoing somatic mutations, whereas, in the remaining two cases, a single point mutation was observed in only 2 of 15 and 21 examined molecular clones of variable heavy (V(H)) chain gene, respectively. These two cases were distantly related to the rest of the activated B cell-like DLCL tumors by gene expression. Our findings validate the concept that lymphoid malignancies are derived from cells at discrete stages of normal lymphocyte maturation and that the malignant cells retain the genetic program of those normal cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954754      PMCID: PMC27813          DOI: 10.1073/pnas.180316097

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Detection of minimal disease using rearranged immunoglobulin heavy chain genes from intermediate- and high-grade malignant B cell non-Hodgkins lymphoma.

Authors:  N van Belzen; P E Hupkes; D Doekharan; M Hoogeveen-Westerveld; L C Dorssers; M B van't Veer
Journal:  Leukemia       Date:  1997-10       Impact factor: 11.528

2.  Diffuse large cell lymphomas are derived from mature B cells carrying V region genes with a high load of somatic mutation and evidence of selection for antibody expression.

Authors:  R Küppers; K Rajewsky; M L Hansmann
Journal:  Eur J Immunol       Date:  1997-06       Impact factor: 5.532

3.  Molecular analysis of the immunoglobulin VH gene rearrangement in a primary cutaneous immunoblastic B-cell lymphoma by micromanipulation and single-cell PCR.

Authors:  S Gellrich; S Golembowski; H Audring; S Jahn; W Sterry
Journal:  J Invest Dermatol       Date:  1997-10       Impact factor: 8.551

Review 4.  Clonal selection and learning in the antibody system.

Authors:  K Rajewsky
Journal:  Nature       Date:  1996-06-27       Impact factor: 49.962

Review 5.  Somatic hypermutation in normal and transformed human B cells.

Authors:  U Klein; T Goossens; M Fischer; H Kanzler; A Braeuninger; K Rajewsky; R Küppers
Journal:  Immunol Rev       Date:  1998-04       Impact factor: 12.988

6.  Analysis of VH genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression.

Authors:  C H Ottensmeier; A R Thompsett; D Zhu; B S Wilkins; J W Sweetenham; F K Stevenson
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

7.  Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma.

Authors:  A Migliazza; S Martinotti; W Chen; C Fusco; B H Ye; D M Knowles; K Offit; R S Chaganti; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

8.  De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation.

Authors:  M Taniguchi; K Oka; A Hiasa; M Yamaguchi; T Ohno; K Kita; H Shiku
Journal:  Blood       Date:  1998-02-15       Impact factor: 22.113

9.  CD10 expression in follicular lymphoma and large cell lymphoma is different from that of reactive lymph node follicles.

Authors:  N M Almasri; J A Iturraspe; R C Braylan
Journal:  Arch Pathol Lab Med       Date:  1998-06       Impact factor: 5.534

10.  Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma.

Authors:  F J Hsu; R Levy
Journal:  Blood       Date:  1995-10-15       Impact factor: 22.113

View more
  58 in total

1.  Cluster analysis of gene expression dynamics.

Authors:  Marco F Ramoni; Paola Sebastiani; Isaac S Kohane
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-24       Impact factor: 11.205

2.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

3.  Splenic marginal zone lymphomas appear to originate from different B cell types.

Authors:  David W Bahler; J Ander Pindzola; Steven H Swerdlow
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

4.  Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).

Authors:  Roshini S Abraham; Susan M Geyer; Marina Ramírez-Alvarado; Tammy L Price-Troska; Morie A Gertz; Rafael Fonseca
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

5.  Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.

Authors:  Patrizia Mondello; Normann Steiner; Wolfgang Willenbacher; Claudio Cerchione; Davide Nappi; Endri Mauro; Simone Ferrero; Salvatore Cuzzocrea; Michael Mian
Journal:  Oncologist       Date:  2018-01-09

6.  Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

Authors:  Silvia Bea; Andreas Zettl; George Wright; Itziar Salaverria; Philipp Jehn; Victor Moreno; Christof Burek; German Ott; Xavier Puig; Liming Yang; Armando Lopez-Guillermo; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; James O Armitage; Randy D Gascoyne; Joseph M Connors; Thomas M Grogan; Rita Braziel; Richard I Fisher; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard Simon; John Powell; Wyndham H Wilson; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Elias Campo; Andreas Rosenwald
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

7.  M17, a gene specific for germinal center (GC) B cells and a prognostic marker for GC B-cell lymphomas, is dispensable for the GC reaction in mice.

Authors:  Dominik Schenten; Angela Egert; Manolis Pasparakis; Klaus Rajewsky
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

Review 8.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

Review 9.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

Review 10.  Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma.

Authors:  Brad Kahl
Journal:  Semin Hematol       Date:  2008-04       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.